指南与共识腹部介入技术与安全USCT

肝硬化患者接受上消化道内镜及腹腔穿刺术时凝血病的管理:多学科Delphi法中持续存在的差距与共识领域

Management of coagulopathy among patients with cirrhosis undergoing upper endoscopy and paracentesis: Persistent gaps and areas of consensus in a multispecialty Delphi.
指南 / 共识 · Hepatology · 2024-04-01

该多学科Delphi法通过11名专家3轮评分,从286项候选指标中确定33项围手术期凝血病管理指标。共识认为诊断性或治疗性腹腔穿刺及诊断性内镜无需检测INR,所有腹腔穿刺和诊断性内镜应避免输注血浆;预防性血小板输注风险超过获益(门诊诊断性腹腔穿刺及诊断性内镜),其他操作在血小板计数>20,000/mm³时风险超过获益。

要点

  • 诊断性或治疗性腹腔穿刺及诊断性内镜无需检测INR。
  • 所有腹腔穿刺和诊断性内镜应避免输注血浆。
  • 门诊诊断性腹腔穿刺及诊断性内镜预防性血小板输注风险超过获益。

核心结论

  • 多学科Delphi法在肝硬化围手术期凝血病管理方面达成多项共识,可为制定统一的实践指标提供基础。

研究设计与样本

  • 多学科改良Delphi法,11名专家小组(包括介入放射学、输血医学、麻醉学、血液学、急诊医学、移植外科及社区实践代表),3轮评分,从286项候选指标中确定33项最终指标。

诊断标准与关键数值

  • 诊断性或治疗性腹腔穿刺及诊断性内镜无需检测INR。
  • 所有腹腔穿刺和诊断性内镜应避免输注血浆。
  • 门诊诊断性腹腔穿刺及诊断性内镜预防性血小板输注风险超过获益。
  • 其他操作在血小板计数>20,000/mm³时预防性血小板输注风险超过获益;血小板计数<20,000/mm³时风险是否超过获益尚不确定。
  • 持续使用阿司匹林对每项操作均允许;氯吡格雷对诊断性和治疗性腹腔穿刺及诊断性内镜允许。

临床应用与阅片要点

  • 诊断性或治疗性腹腔穿刺及诊断性内镜无需检测INR。
  • 所有腹腔穿刺和诊断性内镜应避免输注血浆。
  • 门诊诊断性腹腔穿刺及诊断性内镜预防性血小板输注风险超过获益。
  • 其他操作在血小板计数>20,000/mm³时预防性血小板输注风险超过获益。
  • 持续阿司匹林对每项操作均允许;氯吡格雷对诊断性和治疗性腹腔穿刺及诊断性内镜允许。

局限性

  • 治疗性内镜或急诊内镜的INR检测及血浆输注未达成共识。
  • 其他操作在血小板计数<20,000/mm³时风险是否超过获益尚不确定。
  • 是否允许继续或停止全身抗凝治疗未达成共识。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Patients with cirrhosis have abnormal coagulation indices such as a high international normalized ratio and low platelet count, but these do not correlate well with periprocedural bleeding risk. We sought to develop a consensus among the multiple stakeholders in cirrhosis care to inform process measures that can help improve the quality of the periprocedural management of coagulopathy in cirrhosis. We identified candidate process measures for periprocedural coagulopathy management in multiple contexts relating to the performance of paracentesis and upper endoscopy. An 11-member panel with content expertise was convened. It included nominees from professional societies for interventional radiology, transfusion medicine, and anesthesia as well as representatives from hematology, emergency medicine, transplant surgery, and community practice. Each measure was evaluated for agreement using a modified Delphi approach (3 rounds of rating) to define the final set of measures. Out of 286 possible measures, 33 measures made the final set. International normalized ratio testing was not required for diagnostic or therapeutic paracentesis as well as diagnostic endoscopy. Plasma transfusion should be avoided for all paracenteses and diagnostic endoscopy. No consensus was achieved for these items in therapeutic intent or emergent endoscopy. The risks of prophylactic platelet transfusions exceed their benefits for outpatient diagnostic paracentesis and diagnostic endosopies. For the other procedures examined, the risks outweigh benefits when platelet count is >20,000/mm 3 . It is uncertain whether risks outweigh benefits below 20,000/mm 3 in other contexts. No consensus was achieved on whether it was permissible to continue or stop systemic anticoagulation. Continuous aspirin was permissible for each procedure. Clopidogrel was permissible for diagnostic and therapeutic paracentesis and diagnostic endoscopy. We found many areas of consensus that may serve as a foundation for a common set of practice metrics for the periprocedural management of coagulopathy in cirrhosis.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Tapper EB, Warner MA, Shah RP, et al. Management of coagulopathy among patients with cirrhosis undergoing upper endoscopy and paracentesis: Persistent gaps and areas of consensus in a multispecialty Delphi. Hepatology. 2024. PMID: 38557474. doi:10.1097/HEP.0000000000000856

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。